FPT-SOFTWARE
Global tech corporation FPT affirms its position as a world-class technology enabler for complex business challenges and opportunities with long-term goals defined for 2024 onwards. FPT aims to achieve USD 5 billion in revenue from global IT services in 2030 and reach billion-dollar milestones from a single market, a single vertical industry, and a single contract.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240111379315/en/
From left to right: FPT Software Chairwoman Chu Thi Thanh Ha, FPT CEO Nguyen Van Khoa, FPT Software CEO Pham Minh Tuan (Photo: Business Wire)
On track with this direction, FPT recently became the first Vietnam-headquartered tech firm to surpass one billion USD in revenue from global IT services in 2023. The company embarked on the global expansion journey with the establishment of its subsidiary FPT Software in 1999. Since then, FPT has evolved from developing simple applications to implementing core IT services for its clients; transitioned from a services provider to a comprehensive solution provider; and progressed to higher stages in the technology value chain, with digital transformation and legacy modernization included in its offerings. To achieve its future goals, FPT will leverage its strengths in technical expertise and industry know-how, skilled IT talents, and the growing prominence of its home country Vietnam.
"In the past, FPT had to proactively seek partnerships, but now many big corporations are heading to Vietnam and FPT. Vietnam is rising as a new destination for global businesses. As Vietnam’s pioneering IT firm, we want to reach new heights in the semiconductor industry and artificial intelligence (AI). The future of Vietnam and the world will revolve around semiconductors and AI,” said FPT Chairman Dr. Truong Gia Binh.
"At FPT Software, we believe that world-class stature is built from world-class people. Over the past 25 years, we have strengthened the company's foundation by fostering a one-team spirit, a lifelong learning culture, and a happy working environment. Moving forward, we will continue promoting the development of technology, creativity, domain expertise, and embrace culture and diversity for our workforce of 30,000 talented individuals to keep up with growing market demand and global standards," said FPT Software Chairwoman Chu Thi Thanh Ha.
"Entering the new era as a world-class company, FPT Software is well-positioned to accompany our clients in projects worth millions or billions of dollars. We are committed to developing our high quality global IT workforce to better serve businesses in high-growth fields such as automotive, healthcare, insurance, supply chain, finance, and utilities. We will also embed AI into all services and solutions to enhance agility, productivity, quality and accelerate delivery time for our clients worldwide,” said FPT Software CEO Pham Minh Tuan.
With a track record of success and extensive experience gained over the years, FPT has established itself as a trusted partner to drive advancements in fast-growing fields. In 2023, FPT is one of three companies in Southeast Asia to join SAP’s Regional Strategic Services Partner (RSSP) in the Asia Pacific and Japan region. With over 10 years of experience in automotive software, FPT has built a strong team of over 4,000 engineers and experts for this domain, serving more than 150 clients, including renowned global brands such as Honda, Hyundai, Volvo, VinFast, Ford, Yazaki, LG, Panasonic, NXP. In December 2023, the subsidiary FPT Automotive was officially launched in the United States, after maintaining a growth rate of 40% in recent years as a unit under FPT Software, contributing significantly to its achievement of one billion USD in revenue from the global IT services segment.
About FPT Corporation and FPT Software
FPT Corporation is a global technology corporation and a leader in consulting, providing, and deploying technology and telecommunications services and solutions.
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,000+ clients worldwide, 91 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379315/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom